Abstract
Aim: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. Patients & methods: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. Results: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes. Conclusion: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.
Original language | English |
---|---|
Pages (from-to) | 33-44 |
Number of pages | 12 |
Journal | Future Oncology |
Volume | 15 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 1 2019 |
Keywords
- database
- eribulin mesylate
- metastatic breast cancer
- real-world
- safety
ASJC Scopus subject areas
- Oncology
- Cancer Research